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Abstract
Background: Anemia is a major cause of morbidity in patients with cancer resulting in poor physical performance,
prognosis and therapy outcome. The aim of this study is to assess the efficacy of intravenous (iv) iron administration for
the correction of anemia, for the prevention of exacerbation of anemia, for decreasing blood transfusion rates, and for
the survival of cancer patients.
Methods: Patients with different solid tumor diagnosis who received iv iron during their cancer treatment were
evaluated retrospectively. Sixty-three patients with hemoglobin (Hgb) levels between≥ 9 g/dL, and≤ 10 g/dL, and no
urgent need for red blood cell transfusion were included in this retrospective analysis. The aim of cancer treatment was
palliative for metastatic patients (36 out of 63), or adjuvant or curative for patients with localized disease (27 out of 63).
All the patients received 100 mg of iron sucrose which was delivered intravenously in 100 mL of saline solution,
infused within 30 min, 5 infusions every other day. Complete blood count, serum iron, and ferritin levels before and at
every 1 to 3 months subsequently after iv iron administration were followed regularly.
Results: Initial mean serum Hgb, serum ferritin and serum iron levels were 9.33 g/dL, 156 ng/mL, and 35.9 μg/dL
respectively. Mean Hgb, ferritin, and iron levels 1 to 3 months, and 6 to 12 months after iv iron administration were 10.
4 g/dL, 11.2 g/dL, 298.6 ng/mL, 296.7 ng/mL, and 71.6 μg/dL, 67.7 μg/dL respectively with a statistically significant
increase in the levels (p < 0.001). Nineteen patients (30 %) however had further decrease in Hgb levels despite iv iron
administration, and blood transfusion was necessary in 18 of these 19 patients (28.5 %). The 1-year overall survival rates
differed in metastatic cancer patients depending on their response to iv iron; 61.1 % in responders versus 35.3 % in
non-responders, (p = 0.005), furthermore response to iv iron correlated with tumor response to cancer treatment, and
this relation was statistically significant, (p < 0.001).
Conclusions: Iv iron administration in cancer patients undergoing active oncologic treatment is an effective and safe
measure for correction of anemia, and prevention of worsening of anemia. Amelioration of anemia and increase in
Hgb levels with iv iron administration in patients with disseminated cancer is associated with increased tumor
response to oncologic treatment and overall survival. Response to iv iron may be both a prognostic and a predictive
factor for response to cancer treatment and survival.
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Background
Anemia is an important and common problem in cancer
patients. Besides affecting physical, functional, emotional
well-being and quality of life, it has a negative impact on
treatment outcome, prognosis and survival [1–4]. Bleed-
ing, hemolysis, nutritional deficiencies, renal dysfunction
with decreased erythropoietin synthesis, tumoral infiltra-
tion of bone marrow, myelosuppression from cancer
treatment are among the common causes of anemia in
cancer patients. Besides all the reasons mentioned above,
probably the most important one for the development of
cancer associated anemia is the presence of chronic in-
flammatory state and release of inflammatory cytokines
related to the tumor itself [1–4]. These cytokines such
as interleukin-6 result in erythroid progenitor cell sup-
pression, impaired erythropoietin production, impaired
iron utilization and decreased half-life of red blood cells
[3, 5, 6]. Inflammatory cytokines play a role in iron me-
tabolism through hepcidin synthesis, which is a liver
produced protein, and has a primordial role in iron me-
tabolism [5, 6]. Hepcidin modulates the release of iron
from different cell sources, including enterocytes, mac-
rophages, and hepatocytes to plasma. Through these
effects, hepcidin controls iron absorption from the gut,
the recycling of iron derived from senescent and dam-
aged erythrocytes, and the release of iron from tissue
stores [5, 6].
Anemia in cancer patients may be observed either by
depletion of total body iron stores and low serum ferritin
levels, which is called absolute iron deficiency (AID), or
with normal or elevated total body iron stores and nor-
mal or elevated serum ferritin levels, which is called
functional iron deficiency (FID) [3, 5]. Although oral
iron prescription is a very common practice for anemia
treatment in cancer patients, many of the patients still
require blood transfusion despite adequate oral iron sup-
plementation [7, 8]. Hepcidin mediated inhibition of gut
absorption of iron explains why there is little or no re-
sponse to oral iron supplementation [5, 6]. Intravenous
iron usage in cancer patients is rare, and has been popu-
larized with the approval of erythropoiesis-stimulating
agents (ESAs) in 1997 in oncology, primarily to enhance
the response to erythropoietin [9]. Accordingly, the first
treatment guideline published for cancer associated
anemia in 2002 was primarily for ESAs usage [9, 10].
After popularization of ESAs usage, iv iron has been
used mostly as an adjunct to ESAs [5, 9, 11].
Intravenous administration of iron is more effective
than its oral administration for correction of anemia
especially in patients with FID, which results from fail-
ure to provide iron to the erythroblasts despite sufficient
iron stores [5, 9]. One important reason for this failure
is the trapped iron in the cells; neither dietary iron is
released from the enterocytes in the small intestine, nor
the stored iron is released from the cells of the reticulo-
endothelial system (macrophages, liver) for erythropoi-
esis [9, 12]. The major mechanism behind FID is the
cytokine-mediated increase in hepcidin levels which in turn
reduces the normal function of ferroportin. Ferroportin is a
cell surface transmembrane protein whose function is
transfer of iron from the intracellular stores to transferrin,
the transport protein of iron in the blood [9, 12]. Iv admin-
istration of iron may play a role in overcoming resistance to
hepcidin related reduced iron availability to erythroblasts
and ultimately correction of anemia in these patients. Iv
iron can also overcome the problems of malabsorption of
iron which is quite frequent in cancer patients, due to sur-
gery, radiotherapy and chemotherapy.
Despite the better efficacy of the iv route of iron ad-
ministration, the oral route is still the preferred way of
administration among oncologists for the treatment of
cancer associated anemia. There are serious concerns
among oncologists regarding the iv iron utilization, like
allergic reactions, accumulation of iron in tissues, lack of
knowledge and lack of enough literature about the safety
and efficacy of iv iron use in the treatment of cancer
associated anemia.
We analyzed the role of iv iron administration on the
outcome of patients with localized or metastatic cancer
regarding anemia and survival parameters. The primary
aim of the study was to find out if iv iron could prevent
further exacerbation of anemia in patients undergoing
active cancer treatment, increase the Hgb levels and de-
crease eventual and inevitable blood transfusion rates
secondary to oncologic treatment.
Methods
The medical records of patients with various malignan-
cies who received iv iron during their cancer treatment
were retrospectively evaluated. The study period was be-
tween January 2009 and January 2015. Only anemic
patients with Hgb levels between ≥ 9 g/dL, and ≤ 10 g/dL,
and who did not receive red blood cells transfusion before
were included in this retrospective analysis. Among differ-
ent reasons for intravenous administration of iron, the
most common ones were either the refusal of blood trans-
fusion by the patient, or the prevention of future blood
transfusion secondary to worsening of anemia under
oncologic treatment, or as an alternative to erthyropoietin
use due to its prescription limitations. Sixtythree patients
were identified, 36 had metastatic disease receiving
palliative chemotherapy (CT), radiotherapy (RT) or both,
while 27 had localized disease receiving either adjuvant or
definitive treatment with CT, RT or concomitant chemo-
radiotherapy (CRT).
The most commonly administered chemotherapy
combination during treatment of the patients was;
Docetaxel + Cisplatin (±5FU) (23.8 %). The details of
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other chemotherapy schemas administered during the
study are summarized in Table 1. CT was administered
for a minimum of 3 cycles, either daily for oral chemo-
therapeutics, weekly, every 15 days, every 21 days or
monthly cycles for iv administrations. CT was adminis-
tered either alone for most of the metastatic patients or
concomitantly with radiotherapy for patients with local-
ized disease as curative or adjuvant treatment.
RT was administered to the upper abdomen, pelvic,
thoracic region, or bony areas either alone or concur-
rently with CT in 37 out of 63 patients, either as part of
adjuvant, curative or palliative treatment. Radiation dose
was 30 Gy in 3 Gy fractions per day for palliative treat-
ments, 46 to 60 Gy in 2 Gy fractions per day for adju-
vant or curative treatments. Treatment details are
summarized in Table 1.
Although the study was not randomized and not de-
signed with a control group who did not receive iv iron,
these patients have already generated their own controls
with their Hgb levels before and after the administration
of iv iron.
Only patients receiving treatments with CT, RT, or
CRT were considered for the intervention of iv iron,
while patients receiving no treatment for their cancer or
followed regularly after any treatment were not included
in this study.
Iv iron was administered as 100 mg iron sucrose
(Venofer) in 100 mL of saline solution, within 30 min
of infusion time, 5 infusions every other day. Five-
hundred milligrams of iron sucrose was administered
in total to all the patients while they were undergoing
CT, RT or both.
The study was approved by the local ethics committee
of the Dr. Lutfi Kirdar Kartal Education and Research
Hospital. The patients were followed up regularly by
physical examination and complete blood count, serum
iron, and ferritin levels before, and at every 1 to
3 months subsequently after iv iron infusion.
Overall survival rates were calculated using the
Kaplan-Meier method. Overall survival was measured
from the date of intervention (iv iron administration), to
the time of the last follow-up or date of death. Compari-
son of the survival curves between the groups was
performed with the log-rank test. Repeated measures
test, and chi-square test were used to determine the sig-
nificance of response rate to iv iron administration be-
tween patients with metastatic and localized disease.
Univariate analysis was performed to evaluate the
significance of age, gender, tumor type, and administra-
tion of iv iron in patients with metastatic cancers. A
multivariate analysis was planned depending on the sig-
nificance of the factors. Blood transfusion was per-
formed in patients who did not respond to iv iron, thus
it was not included in the multivariate analysis.
Results
Sixty-three patients (34 female, median age 56 [24-81])
were identified. Demographics of the patients are sum-
marized in Table 2.
Most common tumor types were gastrointestinal can-
cers (31.7 %), followed by breast (23.8 %), lung (17.5 %),
and other tumor types (27 %).
Table 1 Treatment characteristics
Patients Percent
Chemotherapy combinations
Docetaxel + Cisplatin (±5FU) 15 23.8 %
FOLFOX 12 19 %
FEC 10 15.8 %
Paclitaxel + Carboplatin 7 11.1 %
Capecitabine 5 8 %
FUFA 2 3.1 %
Others 12 19.2 %
Radiotherapy areas
Bony areas 15 23.8 %
Pelvic region 10 15.8 %
Thoracic region 7 11.1 %
Upper abdomen 4 6.3 %
Brain 1 1.5 %
Abbreviations: 5FU 5-Fluorouracil, FOLFOX, 5-Fluorouracil, Folinic Acid, Oxaliplatin,
FEC 5-Fluorouracil, Epirubicin, Cyclophosphamide, FUFA 5-Fluorouracil, Folinic Acid
Table 2 Patients characteristics
Patients %
Gender
Female 34 54 %
Male 29 46 %
Median age 56 (range 24–81)
Treatment type
Adjuvant or curative 27 42.9 %
Metastatic 36 57.1 %
Cancer type
Gastrointestinal cancers 20 31.7 %
Breast cancer 15 23.8 %
Lung cancers 11 17.5 %
Others 17 27 %
Mean levels Before iv Iron After iv Iron
Hemoglobin 9.33 g/dL 11.2 g/dL
Serum ferritin 156 ng/mL 296.7 ng/mL
Serum iron levels 35.9 μg/dL 67.7 μg/dL
Blood transfusion 18 (28.6 %)
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Before the administration of iv iron; mean Hgb level for
the whole group was 9.33 ± 0.3 g/dL (range 9–10 g/dL),
mean ferritin level was 156 ± 210 ng/mL (range 2–
943 ng/mL), and mean serum iron level was 35.9 ±
23.1 μg/dL (range 9–107 μg/dL). One to three months
after iv iron administration, the mean Hgb level was
10.4 ± 1.1 g/dL (range 8.6–13.4 g/dL), the mean ferritin
level was 298.6 ± 283 ng/mL (range 6.4–1131 ng/mL),
and mean iron level was 71.6 ± 41.4 μg/dL (range 10–
276 μg/dL). Six to 12 months later, the mean Hgb
level was 11,2 g/dL (range 8.2–15.1 g/dL), the mean
ferritin level was 296.7 ng/mL (range 8–1600 ng/mL),
and mean serum iron level was 67,7 μg/dL (range
10–235 μg/dL). The increase in Hgb, ferritin and iron
levels after iv iron administration was statistically sig-
nificant with a p value <0.001.
Increase in Hgb levels by iv iron administration was
not temporary as in blood transfusion and were sus-
tained throughout the study period. Iv iron administra-
tion increased Hgb levels both in metastatic patients,
and also in patients with localized disease; 1.25 g/dL,
and 2.5 g/dL successively within 6 to 12 months.
Increase in Hgb levels was statistically significant for
both groups with a p < 0.001. Treatment results are sum-
marized in Tables 3, 4 and 5 for all the patients; patients
with metastatic disease treated with palliative intent, and
patients with localized disease treated with adjuvant or
curative intent are reported separately.
Nineteen out of 63 patients (30 %) did not respond to
iv iron with further decrease in their Hgb levels within
3 months after iv iron administration, and 18 out of
these 19 patients (28.5 %) received red blood cell trans-
fusion due to worsening of the anemia and the appear-
ance of anemia associated symptoms.
Increase in Hgb levels after iv iron administration was
more frequent in patients with localized disease treated
either with adjuvant or curative intent (26 out of 27
patients) in comparison to metastatic patients (18 out of
36 patients) p < 0.001. Only 1 out of 27 patients with
localized disease (3.7 %) presented with further decrease
in Hgb levels despite iv iron administration, while 18 out
of 36 patients with metastatic disease (50 %) presented
with further decrease in Hgb levels, and the difference in
Hgb decrease between metastatic and localized disease
was statistically significant (p < 0.001). Estimated means
of Hgb increase between patients presenting with meta-
static and localized tumors is presented in Fig 1.
Median follow up duration for all the patients was
43 months (range 6–60 months). Another important
finding in this retrospective analysis was the survival dif-
ference in metastatic patients depending on their re-
sponse to iv iron. There was statistically significant
difference between 1-year survival rates in patients with
and without increase in Hgb levels after iv iron adminis-
tration (61.1 vs 35.3 %, p = 0.005) (Fig. 2). The 1-year
survival difference was also statistically significant be-
tween metastatic patients who received red blood cell
transfusion, and who did not during the study period
(31.3 vs 63 %, p = 0.004), (Fig. 3). However the survival
figures should be evaluated with caution since the group
was not homogenous with respect to tumor, treatment
and patient characteristics.
In metastatic patients, univariate analysis revealed that
age, gender, tumor type were not statistically significant.
The only factor that affected survival was the adminis-
tration of iv iron (p < 0.001). Thus a multivariate analysis
was not performed.
Another important finding in the study was the correl-
ation of tumor response rates to cancer treatment with
response to iv iron in patients presenting with metastatic
disease. Thirteen out of 18 patients with metastatic
disease who had increased Hgb levels with iv iron ad-
ministration also showed response to their cancer treat-
ment which was verified by RECIST criteria (response
evaluation criteria in solid tumors). On the other hand,
17 out of 18 metastatic patients who did not respond to
iv iron administration also did not respond to their can-
cer treatment either, p < 0,001. Table 6. summarizes the
tumor response to cancer treatment with iv iron re-
sponse in metastatic patients. We think that the re-
sponse to iv iron is both predictive and prognostic for
tumor response to cancer treatment and survival.
Discussion
Intravenous iron use in cancer related anemia has been
popularized with the approval of erythropoiesis-stimulating
agents in 1997 in oncology, and iv iron was shown to
enhance the response to erythropoietin [5, 9, 11]. Since
then ESAs and iv iron combination were commonly used
for the treatment of cancer associated anemia. However
Table 3 Treatment results in all patients
Baseline results 1–3 months results 6–12 months results p:
Hemoglobin
mean/range
9.33 g/dL (9–10 g/dL) 10.4 g/dL (8.6–13.4 g/dL) 11.2 g/dL (8.2–15.1 g/dL) <0,001
Ferritin
mean/range
156 ng/mL (2–943 ng/mL) 298.6 ng/mL (6,4–1131 ng/mL) 296.7 ng/mL (8–1600 ng/mL) <0,001
Iron
mean/range
35.9 μg/dL (9–107 μg/dL) 71.6 μg/dL (10–276 μg/dL) 67.7 μg/dL (10–235 μg/dL) <0,001
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after popularization of ESAs, certain toxicities associated
with their usage, and increased mortality risk has been ob-
served. Among them were increased thromboembolic risk,
cardiovascular adverse events and stimulation of disease
progression in tumor cells with the expression of erythro-
poietin receptors [13–15]. Although ESAs with or without
iv iron reduced the need for red blood cell transfusions,
13 years after their approval in oncology, certain precautions
have been suggested and their use was restricted due to the
above mentioned adverse events [13, 16]. Unfortunately iv
iron administration which was mostly used as an adjuvant to
ESAs to treat cancer associated anemia has been abandoned
with the prescription restrictions of ESAs. Red blood cell
transfusions became popular again for the correction of
cancer associated anemia. However blood transfusion is not
devoid of toxicity and is as harmful as ESAs [17–19].
Iv iron on the other hand is a promising strategy
and is reported to be an effective treatment for anemia
of chronic diseases such as chronic renal failure,
chronic kidney disease and cancer [20–22]. Iv iron
may be an even more effective treatment alternative
for anemia of chronic disease associated with inflam-
mation like cancer, since intravenous administration
may overcome resistance to iron absorption especially
by erythroid cells and iron recycling which are all con-
trolled by hepcidin.
Although iv iron has been demonstrated to be superior
to oral iron in improvement of erythropoietic response
to ESAs, there are limited studies of iv iron alone with-
out ESAs in the treatment of cancer associated anemia
[5, 9, 22–26]. Iv iron together with ESAs not only
increase Hb levels higher than ESAs alone, but also in a
shorter time interval than ESAs, besides these advan-
tages, the addition of iv iron to ESAs decreases blood
transfusion rates significantly compared to ESAs alone
[5, 9, 24, 25].
The first study investigating iv iron alone in oncology
practice was performed and published in 2007, and in-
cluded women with cervical cancer treated with chemo-
radiotherapy [26]. The primary objective of this study
was to prevent exacerbation of anemia and to reduce
blood transfusion by iv iron. In this trial the transfusion
rate dropped from 64 to 40 %. In 2010, another single-
center, prospective, randomized study was published
exploring the effect of iv iron administration on blood
transfusion rates in anemic gynecologic cancer patients
receiving platinum-based chemotherapy [22]. Again, this
was a small study with 22 patients in each arm, but iv
iron resulted in a significant Hgb increase of 0.9 g/dl
and a significant reduction of the transfusion rate from
63.6 to 22.7 %. In both of these studies patients received
iv iron regardless of their initial iron status.
We observed in our retrospective study that, iv iron
provided a significant increase in Hgb levels in already
anemic cancer patients undergoing oncologic treatment
either with CT, RT or both. The increase in Hgb levels
was fast and observed within a month or two after iv
iron administration, and it was more than 1 g/dL. Only
18 out of 63 patients (28.5 %) needed blood transfusion
due to further decrease in their Hgb level and the
appearance of anemia symptoms within 3 months after
iv iron administration. Iv iron prevented high blood
transfusion rates in this patient population since a de-
crease in Hgb level, and a necessity of blood transfusion
would be inevitable with the effect of cancer treatment
probably in all of these patients in the course of time.
Although the study was not randomized and not de-
signed with a control group who did not receive iv iron,
these patients have already generated their own controls
with their Hgb levels before and after the administration
of iv iron. We believe that without any intervention for
anemia correction, the Hgb levels of most of these
Table 4 Treatment results in metastatic patients
Baseline results 1–3 months results 6–12 months results P:
Hemoglobin
mean/range
9.2 g/dL (9–9,7 g/dL) 9.9 g/dL (8.6–13.4 g/dL) 10.45 g/dL (8.2–13.5 g/dL) <0,001
Ferritin
mean/range
236 ng/mL (4–943 ng/mL) 410.3 ng/mL (45–1131 ng/mL) 425.9 ng/mL (10–1600 ng/mL) 0,003
Iron
mean/range
42.6 μg/dL (13–107 μg/dL) 76.2 μg/dL (10–276 μg/dL) 61.5 μg/dL (10–178 μg/dL) <0,001
Table 5 Treatment results in patients with localized disease
Baseline results 1–3 months results 6–12 months results P:
Hemoglobin
mean/range
9.5 g/dL (9–10 g/dL) 11 g/dL (9.3–12.6 g/dL) 12 g/dL (9.3–15.1 g/dL) <0,001
Ferritin
mean/range
49.3 ng/mL (2–296 ng/mL) 149.5 ng/mL (6.4–724 ng/mL) 124.4 ng/mL (8–796 ng/mL) 0,003
Iron
mean/range
27 μg/dL (9–54 μg/dL) 65.4 μg/dL (23–103 μg/dL) 75.9 μg/dL (25–235 μg/dL) <0,001
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patients would gradually get worse with the effect of
cancer treatment and disease per se.
Iv iron although popularized as an adjuvant to ESAs,
is in fact nowadays the most evidence based alternative
to both ESAs and blood transfusion in the treatment of
cancer associated anemia. Acute life-threatening side ef-
fects and lethal anaphylactic reactions are the major
concerns among clinicians with iv iron administration
which is probably the most important factor limiting
their usage [27, 28]. The most common difficulty en-
countered during our study was the fear of medical
personnel in outpatient clinics to administer iv iron
infusion to the patients. However according to United
States Food and Drug Administration (FDA) on adverse
drug events reports, life-threatening adverse drug events
were 0.6 per million doses for iron sucrose, 0.9 for iron
gluconate, and 3.3 for low molecular-weight iron dextran
[25–28]. Life-threatening anaphylactic reactions as with
older iron-dextran solutions have never been observed
in cancer trials [5, 9]. Iron sucrose was reported to have
the lowest adverse events especially the hypersensitivity
reactions [29]. No serious adverse events have been ob-
served in our patients during the study. A recent
observational, prospective study performed in 367 patients
Fig. 1 Estimated means of Hgb increase in patients with metastatic and localized disease after iv iron administration
Fig. 2 Survival curve of metastatic patients with and without increase in Hgb levels after iv iron administration
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with solid or hematologic tumors demonstrated the effi-
cacy and safety of iv iron administration (ferric carboxy-
maltose) [30].
Another concern commonly present among clinicians
is the fear of iron accumulation in patients with normal
iron stores and elevated serum ferritin levels, However
this fear is senseless due to the mechanism of functional
iron deficiency, and due to the doses of iv iron adminis-
tered in the treatment of cancer related anemia. Thus iv
iron is still efficient in patients irrespective of serum iron
and ferritin levels [9, 22]. In this study as well, patients
responded to iv iron irrespective of their baseline serum
iron and ferritin levels.
The deficiency in red blood cells and decreased func-
tional capacity to deliver oxygen to tissues and low
hemoglobin levels result in tumor hypoxia, conferring
resistance to chemotherapy and radiotherapy, decreased
local control, and ultimately decreased survival [31, 32].
Presence of anemia before cancer treatment and correction
of anemia during cancer treatment is closely associated
with survival [33]. We observed a statistically significant 1-
year survival difference in metastatic patients with in-
creased Hgb levels after iv iron administration during their
cancer treatment with CT, RT, or both when com-
pared to the patients without a response (61.1 % vs
35.3 %, p = 0.005). The survival advantage was also
significant in metastatic patients who didn’t receive
blood transfusion when compared to the ones who
received blood transfusion (63 % vs 31.3 %, p = 0.004).
However the survival figures should be evaluated with
caution since the group was not homogenous with re-
spect to treatment, patient and tumor characteristics.
But increase in Hgb levels with iv iron administration may
be both prognostic and predictive factor for survival in
anemic cancer patients undergoing oncologic treatment.
It is worth testing this hypothesis in a prospective trial.
The decrease in Hgb levels despite iv iron administra-
tion was observed less in patients with localized disease
treated with adjuvant or curative intent in comparison
to patients presenting with metastatic disease treated
with palliative intent (3.7 vs 50 %, p < 0.001). We think
that the lower response rate to iv iron in patients with
metastatic disease is due to presence of higher tumor
burden and associated presence of chronic inflammatory
state and more release of inflammatory cytokines with
respect to the patients with localized disease. High
tumor burden and associated inflammation may increase
the serum hepcidin levels in metastatic patients more
than the hepcidin levels in patients with localized
Fig. 3 Survival curve of metastatic patients with and without red blood cell transfusion
Table 6 Correlation of tumor response to cancer treatment with
iv iron response in patients with metastatic disease
Response to treatment Total p:
Yes No
Response to iv iron Yes 13 5 18
No 1 17 18
Total 14 22 36 <0.001
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tumors. A recent study demonstrated that response to iv
iron and erythropoietin is closely related to serum hepci-
din levels [34].
We demonstrated a close relation between response
to iv iron and response to cancer treatment. Tumor re-
sponses to cancer treatment in metastatic patients cor-
related with response to iv iron administration and this
relation was statistically significant (p < 0.001). We
hypothesize that iv iron response is predictive of re-
sponse to oncologic treatment and it can predict re-
sponse to oncologic treatment earlier than clinical and
radiologic evaluation.
Increase in Hgb levels with iv iron administration were
observed in all patients presenting with localized disease
except one (1 out of 27 patients), and red blood cell
transfusion was necessary only in this patient. Iv iron
should be considered in all anemic cancer patients
treated with adjuvant or curative intent since it is very
effective and safe intervention with respect to blood
transfusion. It is very important to prevent adverse ef-
fects of blood transfusion in curatively treated patients.
We don’t know if iv iron administration provides a sur-
vival advantage in patients with localized disease as well,
as in the metastatic patients, since all the patients except
one had increased Hgb levels after iv iron and we need
longer follow-up time in this group. Another important
point to investigate in patients with localized tumors is
the association of ulterior recurrences with the degree of
Hgb increase, but we need more patients and longer
follow-up time to demonstrate this interaction.
Anemia is a common problem in patients with cancer
[3, 4, 35]. Although it has a negative impact on progno-
sis and treatment results, anemia is undertreated and is
not a major concern among oncologists [4, 35]. The
major reason behind this is the lack of effective treat-
ment for anemia and the limitation of ESA’s usage with
the understanding of their harms. However iv iron is a
safe and effective treatment for anemia in patients even
undergoing active cancer treatment either with CT, RT
or both [30, 36]. Increase of hemoglobin with iv iron ad-
ministration is cheap and safe, and it may prevent blood
transfusion and its associated complications. Increase in
Hgb levels by iv iron is not temporary as in blood trans-
fusion, and may increase the survival in metastatic can-
cer patients receiving treatment for their cancer.
The major drawback in our retrospective study is the
heterogeneity of the study population both in respect to
the patient and treatment characteristics, but as a sum-
mary, anemia not responding to iv iron and necessitating
further red blood cell transfusion indicates a worse prog-
nosis and survival. It will be very promising and practice
changing to show the same results in prospectively
designed studies. However even in the absence of such
studies, iv iron is a safe and best evidence based treatment
alternative for anemic cancer patients especially during
their oncologic treatment with CT, RT or both.
Conclusions
Anemia is a common problem in cancer patients and it
has negative impact on prognosis and treatment results.
Transfusion of red blood cells is a common practice
among oncologists for the treatment of cancer related
anemia, and became popular again after the demonstra-
tion of harmful effects of erythropoiesis stimulating
agents. However blood transfusion is not devoid of tox-
icity either. On the other hand intravenous administra-
tion of iron is a promising strategy and is reported to be
effective for the treatment of anemia associated with ma-
lignancy. Amelioration of anemia with intravenous iron
may result in increased response to cancer treatment
and even better survival.
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